Goldman Sachs
AYTU icon

Goldman Sachs’s AYTU BioPharma AYTU Stock Holding History

Goldman Sachs’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13,882
Closed -$42.2K – 5649
2024
Q1 		$42.2K Hold
13,882
– – ﹤0.01% 5339
2023
Q4 		$39.4K Buy
+13,882
New +$38.2K ﹤0.01% 5402
2022
Q2 		– Sell
-2,507
Closed -$54K – 6451
2022
Q1 		$54K Buy
2,507
+464
+23% +$11.5K ﹤0.01% 6253
2021
Q4 		$55K Sell
2,043
-387
-16% -$16.7K ﹤0.01% 6245
2021
Q3 		$140K Buy
2,430
+1,724
+244% +$129K ﹤0.01% 5839
2021
Q2 		$71K Sell
706
-3,192
-82% -$374K ﹤0.01% 6023
2021
Q1 		$592K Buy
+3,898
New +$619K ﹤0.01% 4995
2020
Q4 		– Sell
-116
Closed -$28K – 5477
2020
Q3 		$28K Sell
116
-85
-42% -$21.8K ﹤0.01% 5232
2020
Q2 		$57K Sell
201
-102
-34% -$30.9K ﹤0.01% 5058
2020
Q1 		$91K Buy
+303
New +$58.5K ﹤0.01% 4956

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs's AYTU Position: Q2 2024 in Review

Goldman Sachs sold out of AYTU BioPharma (AYTU) in Q2 2024, closing a stake of 13,882 shares — an estimated $42.2K sold.

Goldman Sachs first reported a position in AYTU in Q1 2020 and held it in 10 quarters. The position peaked at $592K in Q1 2021. 27 funds tracked by Wall St. Rank hold AYTU as of Q2 2024.

  • Goldman Sachs reported no remaining AYTU BioPharma position as of Q2 2024 after selling out during the quarter.
  • Goldman Sachs sold 13,882 AYTU BioPharma shares in Q2 2024, an estimated $42.2K.
  • Goldman Sachs first reported a position in AYTU BioPharma in Q1 2020 and held it in 10 quarters.
  • Goldman Sachs's AYTU BioPharma position peaked at $592K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2024.

Based on Goldman Sachs's 13F filing for Q2 2024, filed 13 Aug 2024.